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Unstructured abstract: In a recent James Lind Alliance Priority Setting Partnership in cystic fibrosis
(CF) the top priority clinical research question was: “What are effective ways of simplifying the
treatment burden of people with CF?” We aimed to summarise the lived experience of treatment
burden and suggest research themes aimed at reducing it. An online questionnaire was co-produced
and responses subjected to quantitative and thematic analysis. 941 survey responses were received
(641 from lay community). People with CF reported a median of 10 (interquartile range: 6-15)
current treatments. Seven main themes relating to simplifying treatment burden were identified.
Treatment burden is high, extending beyond time taken to perform routine daily treatments, with
impact varying according to person-specific factors. Approaches to communication, support,
evaluation of current treatments, service set-up, and treatment logistics (obtaining/administration)
contribute to burden, offering scope for evaluation in clinical trials or service improvement.
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1. Introduction:
The James Lind Alliance Priority Setting Partnership (JLA PSP) in cystic fibrosis (CF) used a robust
methodology to develop the top 10 clinical research questions, through discussions with the clinical
and patient community (1). A number of the top 10 questions are complex and need to be explored
further before they can be transformed into testable hypotheses for clinical study. An example is the
first question: “What are effective ways of simplifying the treatment burden of people with CF”. The
recent US Cystic Fibrosis Foundation Insight CF survey ranked ‘Making it easier to do daily
treatments’ in their top three research priority topics, confirming the relevance of this issue globally
(2). The work described in this paper aimed to:
1) Summarise the lived experience of treatment burden in CF.
2) Suggest themes that can generate research questions for future clinical trials of approaches to
reducing treatment burden.
Some of these results have been previously published as abstracts (3, 4) and shared on social media.
2. Methods:
The UK National Institute for Health Research (NIHR) supports the JLA and agreed to this work under
the branding “James Lind CF2”. The work was led by a steering group, representative of the UK CF
community (both lay and professional) (1). An electronic questionnaire (SurveyMonkeyTM) was co-
produced to understand the size and diversity of the treatment burden in people with CF (PwCF) and
potential strategies to simplify it (Online Supplementary file 1). The survey was designed to be
inclusive, with no minimum age or restrictions on location, and was open for four weeks between
March and April 2018. It was promoted via TwitterTM (@questionCF), professional networks, UK CF
Trust, and NIHR. Responses were subjected to quantitative analysis (closed questions) and thematic
analysis (free text comments). Two reviewers independently reviewed all responses in order to
generate topics that represented recurring themes into which the data was coded. Spearman rank
correlations were used to identify associations between variables.
3. Results:
Of the 941 survey responses we received, 189 (20%) came from PwCF, 452 (48%) came from
relatives or friends of PwCF, and 300 (32%) came from health professionals. Survey participant
characteristics are summarised in Table 1. Mean age of respondents was 41.5y (range 14y-84y);
mean age of PwCF who were responding (or who were the subject of a response), was 15.6y (range
2m-59y). Responses came from 21 countries; with 87% being from UK residents (390/445 where
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location was known). Not all survey participants responded to each question (Online Supplementary
file 2, table E1).
PwCF or their carers reported a median of 10 (interquartile range, IQR, 6-15) current treatments,
with 24% (71/292 respondents) receiving short-term oral medications and 10% (30/292) intravenous
antibiotics at the time of participation. The median total daily time taken for treatments was 2 hours
(IQR 2-3 hours). The total number of treatments was significantly associated with total daily time
spent on treatments (r=0.42, p= <0.001, n=269) - Online Supplementary file 2. In total 70% (240/343)
of PwCF miss out on treatments when busy or tired, most commonly, nebulised therapies and
airway clearance techniques (ACT). When PwCF were asked if they found some treatments more
difficult than others 60% (200/333) agreed. Examples of difficult treatments mentioned frequently
included nebulised therapy, airway clearance, and medication “admin” (i.e. the time, effort and
psychological impact of requesting and obtaining medications and equipment). Difficulties in
obtaining medication were reported by 76% (241/317) of PwCF and/or their relatives or friends.
When PwCF were asked if they thought their treatment plan takes into account their personal
situation, 58% (184/318) felt it did and 22% (71/318) felt it did not, with 63 respondents unsure. For
those to whom questions relating to employment or education were considered applicable, 87%
(202/233) felt that their treatments get in the way of their job or career and 77% (168/217) in the
way of their education. Two thirds (67%; 207/311) reported that their treatments get in the way of
family relationships, relationship with a partner (69%; 162/236), and relationships with friends (75%;
227/304). An impact of treatments on socialising and on sports and hobbies was reported by 81%
(250/308) and 80% (231/289) respectively.
PwCF and professionals listed the same five CF treatments as being “most important” (Table 2a).
There was also agreement between the top two most burdensome treatments (Table 2b): airway
clearance techniques and long term nebulised antibiotics. Key themes relating to why lay and
professional respondents selected ACTs as burdensome included: time taken, dislike, boredom,
battles with children to do ACTs, and a lack of immediate evidence of effect. Similar responses were
received for nebulised antibiotics, with the addition of concerns about side effects and cleaning
nebulisers. Several healthcare professionals voiced concern that selecting the ‘most important’
treatment was impossible as it would be person-specific.
We asked health care professionals: “With the advent of CFTR modulators it may be possible to stop
or reduce some existing treatments for those patients taking these drugs. Would you support a
stopping trial if this was to be carried out?” with endorsement coming from 78% (129/165). This
question was not present in the lay questionnaire.
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Seven main themes relating to simplifying treatment burden were identified through the survey
(table 3).
4. Discussion:
Our survey confirms that the lived experience of treatment burden in CF is high, and extends beyond
time taken to perform routine daily treatments, with an impact on daily life which varies according
to patient and family factors. We have shown concordance between lay and professional
perceptions of both important and burdensome treatments in CF. In the treatments considered
most burdensome (airway clearance and nebulised antibiotics), time burden featured particularly
highly. These ‘top two’ burdensome treatments were also most likely to be missed, supporting the
findings of Sawicki et al(5) in a larger sample size. Our results for time spent on treatment, and
number of treatments, are consistent with previously published surveys of treatment burden in CF
(6-8). Although not explicitly explored in our survey, recent evidence suggests that social support
may reduce perceived treatment burden(9).
Treatment complexity in CF increases with age(10). The demographics of PwCF are changing, with
growing numbers in adult clinics (11), and more living with established disease and its associated
treatment burden. The current landscape for treatment is likely to undergo rapid change over the
next five years, reflecting drugs targeting the underlying molecular defect. Our results show support
amongst CF health care professionals for ‘stopping trials’ of existing treatments for patients on CFTR
modulators. Although beyond the scope of this survey, further exploration of this topic (including
safety, necessity and objective of any trial) within the lay and professional community will be
important. Other opportunities to simplify treatment could be explored in clinical studies, such as
potential interventions to engage patients in shared decision-making and goal setting.
Our study had several limitations. It is possible that some survey responses were biased by the
wording of questions, particularly those with an introductory statement. For some questions it was
felt that this information was necessary to show understanding in order to encourage honest and
open responses. Survey questions went through a rigorous review by both lay and professional
members of the steering group prior to inclusion. A further limitation is the variable number of
respondents answering each survey question. This may have reflected questionnaire design and
length, and we have considered this for subsequent surveys exploring other James Lind Alliance CF
research priorities.
5. Conclusions:
Treatment burden in CF is substantial and multifactorial. We have shown that approaches to
communication, support, evaluation of current treatments, service set-up, and treatment logistics
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(obtaining or administering treatments) contribute to burden and offer scope for evaluation in
clinical trials or service improvement. There is support amongst professionals for a trial of stopping
or reducing some existing treatments for those on CFTR modulators.
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Table 1. Survey participant characteristics
N %
Total survey participants* 941 -
Lay and professional representation
Person with CF 189 20
A parent of a child or children with CF 349 37
Spouse or partner of a person with CF 8 1
Other relative or friend of a person with CF 95 10
Total lay participants 641 68
A health care professional or researcher working
with CF
300 32
Healthcare professional occupation known 289 -
Physiotherapist 64 22
Dietitian 55 19
Respiratory Paediatrician 37 13





Social worker 11 4
Junior Doctor 7 2
General Practitioner 2 1
Geographical location
Participant location known 445 -
UK 389 87
Europe (non UK) 14 3
North America 32 7
South America 2 <1
Asia 2 <1
Australia and New Zealand 5 1
Non-UK unwilling to disclose 1 <1
Age of survey participants
Mean age (all participants), years (range) 41.5 (14-84)
Mean age of PwCF who were responding (or who
were the subject of a response), years (range)
15.6 (2-59)
Legend for table 1. *Total number of participants answering at least one survey question.
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Table 2. Top 5 most important and burdensome treatments
a) Important
Rank Lay n (%) Professional n (%)
1 Pancreatic enzymes 107 (37) Pancreatic enzymes 58 (35)
2 Airway clearance 34 (12) Airway clearance 29 (18)
3 CFTR modulators 27 (9) CFTR modulators 19 (12)
4 Exercise and physical activity 27 (9) Long term nebulised antibiotics 19 (12)
5 Long term nebulised antibiotics 24 (8) Exercise and physical activity 16 (10)
b) Burdensome
Rank Lay n (%) Professional n (%)
1 Airway clearance techniques 68 (24) Airway clearance techniques 66 (42)
2 Long term nebulised antibiotics 53 (19) Long term nebulised antibiotics 43 (27)
3 Pancreatic enzymes 37 (13) Regular intravenous (‘IV’)
antibiotics
10 (6)
4 Regular intravenous (‘IV’) antibiotics 22 (8) Exercise and physical activity 6 (4)
5 Long term antibiotics by mouth 15 (5) Insulin 6 (4)
Legend for table 2: a) Top 5 most important treatments according to lay and professional survey
participants and b) Top 5 treatments to stop in an ideal world without consequence (Lay) or
considered most burdensome (Professional).
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Table 3: Main survey themes from qualitative and quantitative analysis
Topic Example free-text survey response Topic formulations
Individualised /
personalised care
“I don’t think I have ever even been
asked about my life plans by team! In
terms of work commitment they get
annoyed with me if I even try to
consider work, they honestly give the
impression it should all be about my
CF” (pwCF, age 30-35yrs, UK))
i) Lifestyle/work/familial
responsibilities can be
challenging and need to be
accommodated in
treatment plans.
ii) Personalised care plans to take
account of life and
disease progression
stages/patient’s ability to cope
(psycho-socially).
iii) Advances in treatment move




“It’s everything overall. If it’s feeling
difficult and I’m not seeing treatments
make a difference it’s quite hard to feel
motivated to do any of it.” (pwCF, age
25-30, UK)
i) Interventions to support
psychological resilience.
ii) A need for improved
communications.
iii) A recognition that psycho-




“Digital appointments (so less traveling
and missing stuff) and maybe some fun
during nebs and physio. (PwCF, aged
15-20yrs, UK)
i) Use of telehealth interventions
to simplify/reduce treatment
burden.
ii) Use of home-based devices.






“Having to overcome the ‘why do I
have to do this?’ From my 7 year old
grandson. He then tries to do it half
heartedly and we have to nag a wee
bit. Hate having to do this”.
(Grandparent of two children with CF
aged 5-10yrs, UK)
i) Use of gaming/technology to
engage children during treatment.






“The administrative burden of being
your own care coordinator when you
have CF is something that needs to be
acknowledged. It takes far too much
time to get GP, hospital, pharmacy,
[nutrition supplement supplier] and
[home healthcare provider] to talk to
each other and do their jobs. I've
recently ended up crying on the phone
to my GP receptionist on a Friday
afternoon when the pharmacy were
refusing to let me have any [enzymes]
(!). It's also hard to arrange deliveries if
you work as the feed and drug
companies don't do evenings or
weekends” (pwCF, 30-35yrs, UK).
i) Changes to prescription
management systems to
reduce the difficulties PwCF have
getting their
prescribed medicines.





“Generally nebulisers make me cough,
feel tight and sometimes nauseous
without making me feel better. Airway
clearance makes me feel tired, gives
me a headache and often makes me
feel sick but it is worth it in order to
clear enough mucus to be able to
breathe” (PwCF aged 40-45yrs, UK).
i) Better strategies for managing
side-effects.
ii) Managing side effects in a way
that does not escalate the
complexity of treatment
Stopping trials “And there MUST be research on how
to take things away. I hate when new
meds come out now [because] it just
means we have to do more stuff. We
need more things coupled together.
We need treatments prioritized for us.”
(parent of a child with CF age 5-10yrs,
USA)
i) Need for research on how to
take treatments away
